The selective SNM1A inhibitors are cell-active, sensitise cancer cells to a key crosslinking anticancer drug (cisplatin), and lead to trapping of the SNM1A nuclease at sites of ICL-induced damage. The gene discussed is DCLRE1A; the disease is cancer.